Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Right pulmonary artery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Right pulmonary artery. Displaying page 2 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2017-005075-91 Sponsor Protocol Number: STRATIFY-1 Start Date*: 2018-08-30
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: LOW DOSE THROMBOLYSIS, ULTRASOUND ASSISTED THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBOLISM
    Medical condition: Acute Pulmonary Embolism, intermediate high risk (visible impact on right ventricular structure and function, and biochemical markers og myocardial damage according to the European Society of Cardi...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002131-34 Sponsor Protocol Number: GS-US-357-1394 Start Date*: 2015-05-07
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000049-12 Sponsor Protocol Number: STH13889 Start Date*: 2005-03-07
    Sponsor Name:Sheffield teaching Hospitals NHS Foundation Trust
    Full Title: The effects of testosterone therapy in men with pulmonary hypertension
    Medical condition: Pulmonary Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003438-28 Sponsor Protocol Number: AC-065A308 Start Date*: 2016-03-04
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-cont...
    Medical condition: Pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) FR (Completed) DK (Completed) AT (Completed) GB (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002788-80 Sponsor Protocol Number: Uni-Koeln-4243 Start Date*: 2020-09-09
    Sponsor Name:University of Cologne
    Full Title: An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH) (MPO-PAH)
    Medical condition: Group 1: Pulmonary arterial hypertension (PAH) Group 2: Postcapillary pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001210-13 Sponsor Protocol Number: PR IOM-101 Start Date*: 2004-11-19
    Sponsor Name:Bracco Imaging S.p.A
    Full Title: MS-CTA IN PULMONARY ARTERIES FOR THE DETECTION OF PULMONARY EMBOLI AND SUBSEQUENT FOLLOW-UP MS-CTP OF THE LOWER EXTREMITY VEINS FOR THE DETECTION OF DEEP VENOUS THROMBOSIS
    Medical condition: SUSPECTED PULMONARY EMBOLI AND/OR DEEP VENOUS THROMBOSIS MedDRA code for deep venous thrombosis: version 7 LLT 0.913
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003921-13 Sponsor Protocol Number: 12/0368 Start Date*: 2013-06-07
    Sponsor Name:University College London
    Full Title: COMbination therapy for PulmonAry hypertension using RacEcadotril (COMPARE).
    Medical condition: Pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004066-20 Sponsor Protocol Number: AC-055-403 Start Date*: 2015-05-14
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multicenter, single-arm, open-label, phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnet...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000552-25 Sponsor Protocol Number: DS9231-A-U201 Start Date*: 2017-08-07
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE)
    Medical condition: DS9231, also known as TS23, is an inhibitor of alpha2-antiplasmin, incrasing plasmin acitivy and enhances fibrinolysis (thrombolysis) and intended to be used for the treatment of patients with Inte...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006072-32 Sponsor Protocol Number: 2019/ABM/01/00078 Start Date*: 2022-10-05
    Sponsor Name:University Hospital in Poznań
    Full Title: Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction
    Medical condition: Heart Failure with reduced ejection fraction.
    Disease: Version SOC Term Classification Code Term Level
    27.0 10007541 - Cardiac disorders 10078289 Heart failure with reduced ejection fraction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003514-14 Sponsor Protocol Number: CL2-62798-010 Start Date*: 2020-07-06
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute Pulmonary Embolism on heparin
    Medical condition: Acute intermediate high risk pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GR (Prematurely Ended) PT (Completed) HU (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000134-22 Sponsor Protocol Number: MDCO-CAN-15-01 Start Date*: 2021-01-14
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A Prospective, Open-Label, Single-Arm, Multi-Center Study to Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) AND Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis.
    Medical condition: Postoperative neonatal cardiac subjects who are undergoing surgery for placement of systemic-to pulmonary artery palliative shunts (e.g., Blalock-Taussig or central shunt), right ventricle to pulmo...
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000502-11 Sponsor Protocol Number: EKOS-12 Start Date*: 2016-07-21
    Sponsor Name:EKOS Corporation
    Full Title: Study of the Optimum Duration of Acoustic Pulse Thrombolysis (APT) Procedure in the Treatment of Acute Submassive Pulmonary Embolism (OPTALYSE PE).
    Medical condition: Submassive pulmonary embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002692-33 Sponsor Protocol Number: H6D-MC-LVGY Start Date*: 2006-04-10
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterised by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure ...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005100-26 Sponsor Protocol Number: ORION-PH-1 Start Date*: 2017-10-09
    Sponsor Name:Hannover Medical School
    Full Title: A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency an...
    Medical condition: Patients with iron deficiency anemia and pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006787-25 Sponsor Protocol Number: 16122021 Start Date*: 2022-07-06
    Sponsor Name:Rigshospitalet The Heart Center
    Full Title: Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial
    Medical condition: Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10065150 Associated with pulmonary arterial hypertension LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065151 Idiopathic pulmonary arterial hypertension LLT
    24.1 10010331 - Congenital, familial and genetic disorders 10085244 Heritable pulmonary arterial hypertension PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010703-80 Sponsor Protocol Number: AC-063A301 Start Date*: 2009-06-11
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients with Symptomatic Pulmonary ...
    Medical condition: Indication: Symptomatic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024585-22 Sponsor Protocol Number: WILK3 Start Date*: 2011-03-25
    Sponsor Name:Imperial College Academic Healthsciences Centre
    Full Title: What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?
    Medical condition: Idiopathic or familial pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000420-38 Sponsor Protocol Number: 2021-01755 Start Date*: 2023-09-18
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Dapagliflozin in patients with Right Heart Failure (Dapa-RHF)
    Medical condition: Right heart failure defined as (criteria a-c must all be fulfilled): a) Reduced right ventricular systolic function or RV strain defined as at least one of the following b) N-terminal pro-BNP (NT...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 19:11:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA